For example, prior exacerbations, FEV 1 percent predicted, eosinophil count, sex, region, COPD Assessment Test score, prior treatment and reliever medication use were highly significant factors associated with future exacerbation risk, and showed a greater benefit of ICS-containing treatments in patients with higher eosinophil counts, greater number of prior exacerbations and those who had received more prior maintenance therapies [ 24 ].
← all excerpts
DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
1
—
—